Behring Gains US Go-Ahead For AMI Assay
Hoechst subsidiary Behring Diag-nostics has been granted US approval for its cardiac troponin I assay, used for the detection of acute myocardial infarction. The assay is designed to work with Behring's OPUS Plus and OPUS Magnum immunoassay systems. After a myocardial infarction, cardiac troponin I is released into the bloodstream by damaged myocytes.
With this approval, Behring can now offer a complete panel of cardiac marker tests, including myoglobin, CK-MB and total CK. Using the OPUS systems, results from all these tests are available within around 20 minutes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze